TRUVADA

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Nigeria, Netherlands, New Zealand, Poland, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug TRUVADA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII G70B4ETF4S - EMTRICITABINE
 

Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

 
Read more about Emtricitabine
2
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE
 

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

 
Read more about Tenofovir disoproxil

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 TRUVADA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AR03 Tenofovir disoproxil and emtricitabine J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
BR Câmara de Regulação do Mercado de Medicamentos 546820020000617
CA Health Products and Food Branch 02274906
DE Bundesinstitut für Arzneimittel und Medizinprodukte 01380424, 04182185, 05019211, 05121530, 05350526, 05901883, 06773619, 10265395, 10271295, 10709314, 10709343, 11563812, 12442803, 12442826, 12466241, 13577824, 16151356, 16504085, 16678891, 16678945
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 4801-MEE-0819
EE Ravimiamet 1208450, 1460102
ES Centro de información online de medicamentos de la AEMPS 04305001
FI Lääkealan turvallisuus- ja kehittämiskeskus 023063
FR Base de données publique des médicaments 69481664
GB Medicines & Healthcare Products Regulatory Agency 90981
HK Department of Health Drug Office 56076, 57749
IL מִשְׂרַד הַבְּרִיאוּת 4972
JP 医薬品医療機器総合機構 6250103F1036
LT Valstybinė vaistų kontrolės tarnyba 1031459, 1052078, 1059512, 1089617
MX Comisión Federal para la Protección contra Riesgos Sanitarios 245M2005
NG Registered Drug Product Database 04-8774
Switch country to NG in order to find specific presentations of TRUVADA
NL Z-Index G-Standaard, PRK 146560
NZ Medicines and Medical Devices Safety Authority 11880
PL Rejestru Produktów Leczniczych 100146769
SG Health Sciences Authority 14147P
TR İlaç ve Tıbbi Cihaz Kurumu 8698760090021
US FDA, National Drug Code 61919-669, 61958-0701, 61958-0703, 61958-0704, 61958-0705, 63629-7581, 67296-1237, 68071-2112, 70518-0097
ZA Health Products Regulatory Authority 41/20.2.8/0171

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.